Yarrow Bioscience (YARW) Net Shares Issued and Repurchased (2016 - 2020)
Yarrow Bioscience's (YARW) quarterly Net Shares Issued and Repurchased came in at $1.5 million in Q1 2020, up 1245.68% on a YoY basis from $108881.0 in Q2 2019, and up 181.31% quarter-over-quarter from $520850.0 in Q4 2019.
Analysis
Yarrow Bioscience (YARW) Net Shares Issued and Repurchased (2016 - 2020) Analysis & Trends
Yarrow Bioscience (YARW) has reported Net Shares Issued and Repurchased for 5 consecutive years, with $1.5 million the latest figure, recorded in Q1 2020.
- For the quarter ending Q1 2020, Net Shares Issued and Repurchased rose 1245.68% year-over-year to $1.5 million; the trailing twelve-month figure through Mar 2020 stood at $1.5 million (up 1245.68% YoY), and the FY2019 full-year result was $520850.0, down 69.36% from the prior year.
- Net Shares Issued and Repurchased rose to $1.5 million in Q1 2020 per YARW's latest filing, from $520850.0 in the prior quarter.
- Across five years, Net Shares Issued and Repurchased topped out at $1.7 million in Q4 2018 and bottomed at $108881.0 in Q1 2019.
- Historically, Net Shares Issued and Repurchased has averaged $1.1 million across 5 years, with a median of $1.3 million in 2017.
- The sharpest annual moves came in 2019 and 2020: Net Shares Issued and Repurchased plunged 69.36% in 2019, then soared 1245.68% in 2020.
- Over 5 years, Net Shares Issued and Repurchased stood at $1.5 million in 2016, then dropped by 29.95% to $1.0 million in 2017, then soared by 63.41% to $1.7 million in 2018, then slumped by 69.36% to $520850.0 in 2019, then soared by 181.31% to $1.5 million in 2020.
- According to Business Quant data, Net Shares Issued and Repurchased over the past three periods registered $1.5 million, $520850.0, and $108881.0 for Q1 2020, Q4 2019, and Q1 2019 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Shares Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | - |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | - |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | -3.07 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | - |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | - |
| 10 | Yarrow Bioscience | 25.25 Mn | 2.33 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2020 | 1.47 Mn |
| Dec 31, 2019 | 520,850.00 |
| Mar 31, 2019 | 108,881.00 |
| Dec 31, 2018 | 1.70 Mn |
| Dec 31, 2017 | 1.04 Mn |
| Dec 31, 2016 | 1.49 Mn |